Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting

Repare Therapeutics Inc RPTX announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations.
Data were presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
In the study, the data cutoff on August 15 included 101 patients.
While RP-3500 looked safe and well-tolerated, the most common treatment-emergent adverse events were mild to moderate anemia.
14.5% of the patients who received the recommended weekly schedule of 3 days on/4 days off experienced Grade 3 anemia.
Antitumor activity was observed in patients with tumors harboring SNIPRX predicted genomic alternations at doses over 100mg across multiple tumor types and included patients after PARP inhibitor failure.
Meaningful clinical benefit was observed in 49% of 69 patients with available scans, including 12 patients with tumor responses, 14 with ongoing stable disease for at least 16 weeks, and 8 with stable disease after two radiological evaluations, but had demonstrated a decrease in tumor markers and tumor shrinkage of less than 30%.
Promising deep molecular responses in circulating tumor DNA (ctDNA) were observed.
Last week, Repare clarified an inadvertently released abstract on the trial that included data from a very early cutoff date.
Price Action: RPTX shares closed 6.58% lower at $20.46 on Friday.